Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 899 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of the Cervix Clear all

Conditions: Cervical Cancer
Interventions: Colposcopy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Cervical Cancer
Interventions: carboplatin, docetaxel; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cervical Cancer, Radiation Toxicity
Interventions: Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy, External beam radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 17
States / cities: Jacksonville, Florida • Jacksonville Beach, Florida • Jascksonville, Florida + 11 more

Conditions: Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Interventions: ADRX-0706; Drug
Lead sponsor: Adcentrx Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Los Angeles, California • St. Petersburg, Florida • Tampa, Florida + 8 more

Conditions: Cervical Cancer
Interventions: HPV testing of women for cervical cancer screening; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years to 49 Years · Female only
Enrollment: 9,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Cancer
Interventions: filgrastim, paclitaxel, topotecan hydrochloride; Biological · Drug
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Cancer, Precancerous Condition
Interventions: Multispectral Digital Colposcope (MDC); Device
Lead sponsor: British Columbia Cancer Agency; Other
Eligibility: 18 Years and older · Female only
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Brooklyn, New York • El Paso, Texas

Conditions: Uterine Cervical Neoplasms, Sexually Transmitted Diseases
Interventions: Not listed
Lead sponsor: Fenway Community Health; Other
Eligibility: 21 Years to 64 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cervical Cancer
Interventions: patient Navigation; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer
Interventions: HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
Interventions: capecitabine, brachytherapy, radiation therapy; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Cervical Cancer
Interventions: DVD, Promotora; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 21 Years to 64 Years · Female only
Enrollment: 451 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gynecologic Cancer
Interventions: Receive routine instructions, Telehealth-based instructional visit and receive routine instructions; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 25 Years to 85 Years · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions: NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more

Conditions: Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
Interventions: triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography; Drug · Radiation · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage I Cervical Cancer AJCC v6 and v7, Stage IA Cervical Cancer AJCC v6 and v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7
Interventions: Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Drug · Radiation · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 698
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 433 more

Conditions: Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
Interventions: NGM707, NGM707 plus pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more

Conditions: Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Interventions: Fecal Microbiota Transplantation, Loperamide; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Cancer
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions: Patient-Reported Outcomes-Informed Symptom Management System (PRISMS); Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
Interventions: Bevacizumab, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 103
States / cities: Burbank, California • Sacramento, California • Colorado Springs, Colorado + 73 more

Conditions: Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma, Rectal Cancer, Breast Cancer, Colorectal Cancer, Mouth Cancer
Interventions: LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter; Drug · Device
Lead sponsor: Light Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 6
States / cities: Tucson, Arizona • Detroit, Michigan • Greenville, North Carolina + 2 more

Conditions: Advanced Solid Tumors, Merkel Cell Carcinoma
Interventions: FF-10850 Topotecan Liposome Injection; Drug
Lead sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Scottsdale, Arizona • Denver, Colorado • Boston, Massachusetts + 4 more

Conditions: Breast Cancer, Cervical Cancer
Interventions: e-CHEC-uP, CHEC-uP; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia

Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix

Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer

A Study of ADRX-0706 in Select Advanced Solid Tumors

Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique

Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix

Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection

Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients

Patient Navigation in the Safety Net:CONNECTeDD

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

Cervical Cancer Screening Among Hispanic Women

Telehealth & HPV Self-Collection

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Radical Trachelectomy for Women With Early Stage Cervical Cancer

Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English